Strategic partnerships The Catapult collaborates with academia, industry partners, Innovate UK and other national catapults, indicating a readiness to engage in joint ventures and co-development programs that could be opportunities for strategic alliances, licensing, or joint funding of cell and gene therapy projects.

UK as hub With a stated aim to make the UK the most compelling place to develop and commercialise advanced therapies, there is potential to position as a primary gateway for international biologics firms seeking UK-based clinical, process development, manufacturing and regulatory support.

End-to-end capabilities Capabilities span clinical trials enablement, process development, manufacturing, regulatory, health economics and market access, suggesting cross-sell opportunities to biotech and pharma companies needing a one-stop solution for translating R&D into commercial therapies.

Technology readiness A tech stack including cloud, data platforms and AI tools signals an openness to digital health solutions, data analytics, and scalable manufacturing efficiency; potential sales angles include digital workflow optimization, data integration services, and AI-assisted development or manufacturing.

Global collaborations Recent partnerships and international collaboration activity (e.g., with Perceptual Robotics, C2MI, and national entities) demonstrate a track record of collaboration and exposure to global markets, presenting opportunities to propose multi-region programs, licensing, or joint ventures.